Stock ONCT ONCTERNAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
8.25 USD -3.45% Intraday chart for Oncternal Therapeutics, Inc. -4.07% -23.07%
Apr. 18 Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer CI
Apr. 15 HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating MT

Business Summary

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Number of employees: 29

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Oncology Therapies
100.0 %
1 100.0 % 1 100.0 % -47.32%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1 100.0 % 1 100.0 % -47.32%

Managers

Managers TitleAgeSince
James Breitmeyer FOU
 Founder 70 96-12-31
Richard Vincent DFI
 Director of Finance/CFO 61 17-03-31
Salim Yazji CTO
 Chief Tech/Sci/R&D Officer 55 21-05-16
Rajesh Krishnan CTO
 Chief Tech/Sci/R&D Officer 51 19-08-27
Pablo Urbaneja PRN
 Corporate Officer/Principal - 21-06-30
Anita Wiseth HRO
 Human Resources Officer - 21-02-28
Chase Leavitt LAW
 General Counsel 42 21-04-11

Members of the board

Members of the board TitleAgeSince
David Hale FOU
 Founder 75 96-12-31
Dan Kisner BRD
 Director/Board Member 77 19-06-06
Rosemary Mazanet BRD
 Director/Board Member 67 21-01-26
James Breitmeyer FOU
 Founder 70 96-12-31
William LaRue BRD
 Director/Board Member 73 17-11-30
Michael Carter BRD
 Director/Board Member 86 19-06-06
Charles Theuer BRD
 Director/Board Member 60 18-04-30
Jill DeSimone BRD
 Director/Board Member 68 23-01-02
Robert Wills BRD
 Director/Board Member 70 19-06-06
Xin Nakanishi BRD
 Director/Board Member 62 18-10-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 2,959,645 2,700,684 ( 91.25 %) 0 91.25 %

Shareholders

NameEquities%Valuation
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
5.988 %
177,222 5.988 % 2 M $
Vanguard Global Advisers LLC
4.833 %
143,045 4.833 % 1 M $
Millennium Management LLC
3.473 %
102,795 3.473 % 925 155 $
BlackRock Institutional Trust Co. NA
1.327 %
39,285 1.327 % 353 565 $
James Breitmeyer
1.108 %
32,787 1.108 % 295 083 $
Hale BioPharma Ventures LLC
1.003 %
29,673 1.003 % 267 057 $
Richmond Brothers, Inc.
0.8346 %
24,702 0.8346 % 222 318 $
BIT Capital GmbH
0.7045 %
20,850 0.7045 % 187 650 $
Renaissance Technologies LLC
0.5528 %
16,360 0.5528 % 147 240 $
Robert Wills
0.3379 %
10,000 0.3379 % 90 000 $

Company contact information

Oncternal Therapeutics, Inc.

12230 El Camino Real Suite 230

92130, San Diego

+

http://www.oncternal.com
address Oncternal Therapeutics, Inc.(ONCT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Oncternal Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.25 USD
Average target price
30.67 USD
Spread / Average Target
+271.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ONCTERNAL THERAPEUTICS, INC. Stock Oncternal Therapeutics, Inc.
-23.07% 22.98M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 43.84B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 41.68B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 41.25B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 27.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 25.53B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 12.29B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.15B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ONCT Stock
  4. Company Oncternal Therapeutics, Inc.